{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ardelyx, Inc. Stock Hits Day Low of $5.49 Amid Price Pressure
Ardelyx, Inc. has faced significant challenges, with its stock declining 7.55% today and 11.27% over the past week. Financial metrics reveal a pre-tax loss of USD 19.08 million and negative EBITDA, indicating ongoing difficulties. Despite a strong three-year performance, the company has underperformed in the past year.
Ardelyx, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Ardelyx, Inc., a small-cap pharmaceutical company, has experienced notable stock fluctuations, with a recent closing price of $5.54. The stock's performance has varied significantly over different periods, showing a year-to-date return of 9.27%, while underperforming over the past year compared to the S&P 500.
Ardelyx, Inc. Hits Day Low of $5.49 Amid Price Pressure
Ardelyx, Inc. has faced notable challenges, with shares declining significantly today and over the past week. The company reported a pre-tax loss of USD 19.08 million, alongside a decrease in net profit. Despite a positive year-to-date performance, it has underperformed compared to the broader market.
Is Ardelyx, Inc. technically bullish or bearish?
As of September 9, 2025, Ardelyx, Inc. has a bullish trend supported by positive indicators, despite a bearish weekly RSI, with a 10.50% return over the past month and a remarkable 390.08% return over the past three years compared to the S&P 500's 2.33% and 70.41%, respectively.
Is Ardelyx, Inc. overvalued or undervalued?
As of November 6, 2019, Ardelyx, Inc. is considered risky and appears overvalued due to negative profitability indicators and high valuation ratios compared to peers, despite a strong 3-year return of 390.08% and recent volatility.
Is Ardelyx, Inc. overvalued or undervalued?
As of November 6, 2019, Ardelyx, Inc. is considered overvalued and classified as "risky" due to significant financial distress, reflected in its high Price to Book Value of 6.04 and poor stock performance with a year-to-date return of -28.40%, compared to the S&P 500's 2.44%.
Is Ardelyx, Inc. technically bullish or bearish?
As of May 2, 2025, Ardelyx, Inc. is in a bearish trend across multiple time frames, with indicators like MACD, moving averages, and Bollinger Bands all reflecting significant weakness in the stock's performance.
Who are in the management team of Ardelyx, Inc.?
As of March 2022, the management team of Ardelyx, Inc. includes Independent Chairman David Mott, CEO Michael Raab, and several Independent Directors: Robert Bazemore, William Bertrand, Geoffrey Block, Onaiza Cadoret-Manier, and Jan Lundberg. This team provides governance and strategic direction for the company.
What does Ardelyx, Inc. do?
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cardiorenal and gastrointestinal diseases. As of March 2025, it reported net sales of $74 million and a net loss of $41 million, with a market cap of approximately $849.36 million.
How big is Ardelyx, Inc.?
As of Jun 18, Ardelyx, Inc. has a market capitalization of 849.36 million, with net sales of 361.70 million and a net profit of -53.76 million over the latest four quarters. As of Dec'24, the company reported shareholder's funds of 173.29 million and total assets of 435.75 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
